Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03730961 | An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic | PHASE2 | COMPLETED | 23 | — | — | Jan 17, 2019 | Jan 9, 2020 | Feb 26, 2021 | 2 | United Kingdom |
The total volume of urinary output 4 hours after 40 mg furosemide bolus given to participants with HFrEF while on BMS-986231 compared to placebo: absolute difference in total volume and % change from placebo. Sequence 1: Placebo in period 1, drug in period 2 Sequence 2: Drug in period 1, placebo in period 2
| Arm | Type | Description |
|---|---|---|
| Placebo+Diuretic to BMS-986231+Diuretic | EXPERIMENTAL | Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods |
| BMS-986231+Diuretic to Placebo+Diuretic | EXPERIMENTAL | Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods |
| Name | Type | Description |
|---|---|---|
| BMS-986231 | DRUG | Intravenous administration |
| Furosemide | DRUG | Intravenous administration |
| Placebo | DRUG | Intravenous administration |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Left ventricular ejection fraction \<45%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan with...